SI-BONE Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Für SI-BONE wird ein Gewinn- und Umsatzwachstum von 12.6% bzw. 14% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 14.1% pro Jahr steigen soll.
Wichtige Informationen
12.6%
Wachstumsrate der Gewinne
14.06%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.2% |
| Wachstumsrate der Einnahmen | 14.0% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 12 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...Analyseartikel • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...Recent updates
Analyseartikel • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...
Narrativ-Update • Apr 12
SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).Narrativ-Update • Mar 29
SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.Narrativ-Update • Mar 11
SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).Narrativ-Update • Feb 25
SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).Narrativ-Update • Jan 19
SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.Narrativ-Update • Jan 04
SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.Narrativ-Update • Dec 19
SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.Analyseartikel • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...Analyseartikel • Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...Analyseartikel • Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...Analyseartikel • May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...Analyseartikel • Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Neues Narrativ • Mar 26
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.Analyseartikel • Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...Analyseartikel • Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...Analyseartikel • Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyseartikel • Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...Analyseartikel • Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...Analyseartikel • Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jan 01
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 304 | -11 | N/A | 30 | 3 |
| 12/31/2027 | 267 | -17 | 19 | 21 | 8 |
| 12/31/2026 | 232 | -20 | -6 | -2 | 8 |
| 3/31/2026 | 206 | -17 | -6 | 2 | N/A |
| 12/31/2025 | 201 | -19 | -9 | -1 | N/A |
| 9/30/2025 | 194 | -22 | -11 | -1 | N/A |
| 6/30/2025 | 185 | -24 | -13 | -3 | N/A |
| 3/31/2025 | 177 | -27 | -20 | -10 | N/A |
| 12/31/2024 | 167 | -31 | -23 | -12 | N/A |
| 9/30/2024 | 157 | -37 | -25 | -16 | N/A |
| 6/30/2024 | 151 | -41 | -26 | -18 | N/A |
| 3/31/2024 | 144 | -43 | -23 | -16 | N/A |
| 12/31/2023 | 139 | -43 | -27 | -19 | N/A |
| 9/30/2023 | 132 | -44 | -32 | -23 | N/A |
| 6/30/2023 | 124 | -48 | -38 | -28 | N/A |
| 3/31/2023 | 117 | -55 | -49 | -39 | N/A |
| 12/31/2022 | 106 | -61 | -51 | -42 | N/A |
| 9/30/2022 | 100 | -65 | -57 | -48 | N/A |
| 6/30/2022 | 96 | -66 | -57 | -50 | N/A |
| 3/31/2022 | 92 | -62 | -50 | -44 | N/A |
| 12/31/2021 | 90 | -57 | -46 | -40 | N/A |
| 9/30/2021 | 87 | -51 | -40 | -35 | N/A |
| 6/30/2021 | 85 | -45 | -36 | -31 | N/A |
| 3/31/2021 | 77 | -43 | -34 | -31 | N/A |
| 12/31/2020 | 73 | -44 | -33 | -31 | N/A |
| 9/30/2020 | 71 | -44 | -34 | -32 | N/A |
| 6/30/2020 | 67 | -46 | -36 | -33 | N/A |
| 3/31/2020 | 69 | -42 | -37 | -34 | N/A |
| 12/31/2019 | 67 | -38 | N/A | -32 | N/A |
| 9/30/2019 | 63 | -35 | N/A | -29 | N/A |
| 6/30/2019 | 60 | -28 | N/A | -24 | N/A |
| 3/31/2019 | 58 | -23 | N/A | -17 | N/A |
| 12/31/2018 | 55 | -17 | N/A | -15 | N/A |
| 9/30/2018 | 54 | -17 | N/A | -12 | N/A |
| 6/30/2018 | 52 | -18 | N/A | -14 | N/A |
| 3/31/2018 | 49 | -21 | N/A | -17 | N/A |
| 12/31/2017 | 48 | -23 | N/A | -18 | N/A |
| 3/31/2017 | 44 | -21 | N/A | -16 | N/A |
| 12/31/2016 | 42 | -21 | N/A | -17 | N/A |
| 3/31/2016 | 40 | -27 | N/A | -25 | N/A |
| 12/31/2015 | 41 | -28 | N/A | -27 | N/A |
| 9/30/2015 | 42 | -32 | N/A | -27 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SIBN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: SIBN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: SIBN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: SIBNDie Einnahmen des Unternehmens (14% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: SIBNDie Einnahmen des Unternehmens (14% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SIBN in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/18 19:04 |
| Aktienkurs zum Tagesende | 2026/05/15 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
SI-BONE, Inc. wird von 16 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |